Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2012; 33(03): 155-160
DOI: 10.4103/0971-5851.103142
ORIGINAL ARTICLE

Pediatric glioblastoma multiforme: A single-institution experience

Mansour Ansari
Department of Radiation Oncology, Student Research Committee, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
,
Hamid Nasrolahi
Department of Radiation Oncology, Student Research Committee, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
,
Amir-Abbas Kani
Department of Radiation Oncology, Student Research Committee, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
,
Mohammad Mohammadianpanah
Department of Radiation Oncology, Student Research Committee, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
,
Niloofar Ahmadloo
Department of Radiation Oncology, Student Research Committee, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
,
Shapour Omidvari
Department of Radiation Oncology, Student Research Committee, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
,
Ahmad Mosalaei
Department of Radiation Oncology, Student Research Committee, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

Background: Glioblastoma multiforme (GBM) is the most common astrocytoma in adults and has a poor prognosis, with a median survival of about 12 months. But, it is rare in children. We report our experience on the pediatric population (20 years or younger) with GBM. Patients and Methods: Twenty-three patients with GBM who were treated at our hospital during 1990-2008 were evaluated. Results: The mean age was 15.2 years, and the majority of them (14/23) were male. All had received radiotherapy and some had also received chemotherapy. The mean survival was 16.0 months. Two cases survived more than 5 years. Age, radiation dose and performance status were significantly related to survival. Conclusion: GBM in pediatric patients were not very common in our center, and prognosis was unfavorable.

Keywords

Glioblastoma multiforme - pediatrics - survival


Publication History

Article published online:
02 August 2021

© 2012. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Katz DS, Poe LB, Winfield JA, Corona RJ Jr. A rare case of cerebellar glioblastoma multiforme in childhood: MR imaging. Clin Imaging 1995;19:162-4.
  • 2 Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK, et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 2009;18:1061-83.
  • 3 Sathornsumetee S, Rich JN. New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther 2006;6: 1087-104.
  • 4 Noda SE, El-Jawahri A, Patel D, Lautenschlaeger T, Siedow M, Chakravarti A. Molecular advances of brain tumors in radiation oncology. Semin Radiat Oncol 2009;19:171-8.
  • 5 Robins HI, Chang S, Butowski N, Mehta M. Therapeutic advances for glioblastoma multiforme: current status and future prospects. Curr Oncol Rep 2007;9:66-70.
  • 6 Borgo MC, Pereira JL, Lima FB, Brandão RA, Carvalho GT, Costa BS. Glioblastoma multiforme in childhood: a case report. Clinics (Sao Paulo) 2010;65:923-5.
  • 7 Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
  • 8 Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al. Long-term survival with glioblastoma multiforme. Brain 2007;130:2596-606.
  • 9 Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol 2008;10:79-87.
  • 10 Robins HI, Chang S, Butowski N, Mehta M. Therapeutic advances for glioblastoma multiforme: current status and future prospects. Curr Oncol Rep 2007;9:66-70.
  • 11 Shinoda J, Sakai N, Murase S, Yano H, Matsuhisa T, Funakoshi T. Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol 2001;52:161-71.
  • 12 Buckner JC, Brown PD, O′Neill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. Mayo Clin Proc 2007;82:1271-86.
  • 13 McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD, Quinones-Hinojosa A. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery 2009;65:463-9
  • 14 Ganigi PM, Santosh V, Anandh B, Chandramouli BA, Sastry Kolluri VR. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: A study of 54 patients. Pediatr Neurosurg 2005;41:292-9.
  • 15 Piroth MD, Gagel B, Pinkawa M, Stanzel S, Asadpour B, Eble MJ. Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors. Strahlenther Onkol 2007;183: 695-702.
  • 16 Odrazka K, Petera J, Kohlova T, Dolezel M, Vaculikova M, Zouhar M, et al. Prognostic impact of hemoglobin level prior to radiotherapy on survival in patients with glioblastoma. Strahlenther Onkol 2003;179:615-9.
  • 17 Villavicencio AT, Burneikiene S, Romanelli P, Fariselli L, McNeely L, Lipani JD, et al. Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme: a multicenter experience. Neurosurg Rev 2009;32:417-24.
  • 18 Li SW, Qiu XG, Chen BS, Zhang W, Ren H, Wang ZC, et al. Prognostic factors influencing clinical outcomes of glioblastoma multiforme. Chin Med J (Engl) 2009;122:1245-9.
  • 19 Sánchez-Herrera F, Castro-Sierra E, Gordillo-Domínguez LF, Vaca-Ruiz MA, Santana-Montero B, Perezpeña-Diazconti M, et al. Glioblastoma multiforme in children: experience at Hospital Infantil de Mexico Federico Gomez. Childs Nerv Syst 2009;25:551-7.
  • 20 Dohrmann GJ, Farwell JR, Flannery JT. Glioblastoma multiforme in children. J Neurosurg 1976;44:442-8.
  • 21 Grovas AC, Boyett JM, Lindsley K, Rosenblum M, Yates AJ, Finlay JL. Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: Report from the Children′s Cancer Group. Med Pediatr Oncol 1999;33:83-7.
  • 22 Perkins SM, Rubin JB, Leonard JR, Smyth MD, El Naqa I, Michalski JM, et al. Glioblastoma in children: A single institution experience. Int J Radiat Oncol Biol Phys 2011;80: 1117-21.
  • 23 Suri V, Das P, Pathak P, Jain A, Sharma MC, Borkar SA, et al. Pediatric glioblastomas: A histopathological and molecular genetics study. Neuro Oncol 2009;11:274-80.
  • 24 Marchese MJ, Chang CH. Malignant astrocytic gliomas in children. Cancer 1990;65:2771-8.